This article covers:
• Metropolis Healthcare’s revenue growth
• Innovative cervical cancer screening
• Collaboration with Roche Diagnostics
• Micro-marketing strategies
• Expansion in diagnostics sector
Innovative Cervical Cancer Screening Approach
In a significant leap towards innovative healthcare diagnostics, Metropolis Healthcare has joined forces with Roche Diagnostics to introduce a pioneering self-sampling HPV DNA test for cervical cancer screening in India. This collaboration aims to tackle cervical cancer, a major health concern for Indian women, by making early screening more accessible and comfortable. The introduction of self-sampling tests is a game-changer, empowering women to take proactive steps towards their health from the comfort of their homes.
The significance of this move cannot be overstated, as cervical cancer remains a preventable disease with early detection and vaccination. However, the lack of widespread screening and awareness has led to it remaining a leading cause of cancer-related deaths among women in India. By enabling easier access to screening tools, Metropolis Healthcare and Roche Diagnostics are setting a new standard in the fight against cervical cancer.
Impressive Revenue Growth and Strategic Expansions
Metropolis Healthcare’s innovative approach extends beyond medical advancements into strategic market growth. In the third quarter of 2025, Metropolis reported an impressive 11% year-on-year revenue growth, driven by a 4.1% increase in patient volumes. This growth is attributed to strategic adjustments in product mix and pricing, as well as a 6% increase in test volume growth. Such performance highlights the company’s ability to leverage innovation and strategic market positioning to enhance its financial health and market presence.
The company’s focus on micro-marketing strategies has been particularly noteworthy. By tailoring its services and offerings to meet the specific needs of micro markets, Metropolis has seen a significant 26% revenue boost. This localized approach not only allows the company to enhance its service offerings but also to deepen its penetration into key regions, addressing the unique needs of diverse patient demographics.
Expanding Access to Early Detection Across India
The partnership between Metropolis Healthcare and Roche Diagnostics represents a landmark effort to expand access to early detection of cervical cancer across India. By introducing advanced screening tools like the HPV DNA test, the collaboration aims to bridge the healthcare gap in India, especially in tier 2 and tier 3 cities. These regions have historically faced significant challenges in healthcare access, particularly in diagnostics, due to limited infrastructure, a shortage of trained professionals, and low awareness about preventive healthcare.
Metropolis Healthcare’s CEO, Surendran Chemmenkotil, emphasizes the company’s commitment to improving its footprint across India by customizing its services for these micro markets. The diagnostic industry in India, valued at approximately US$13 billion in FY23, is ripe for such innovative approaches that not only improve service delivery but also contribute to the overall health of the population by facilitating early diagnosis and treatment.
Conclusion
Metropolis Healthcare’s strategic partnership with Roche Diagnostics and its focus on micro-marketing strategies underscore the company’s commitment to innovation and market expansion. By introducing self-sampling HPV DNA tests for cervical cancer screening, Metropolis is not only enhancing its portfolio of diagnostic services but also playing a crucial role in improving women’s health outcomes in India. With its impressive revenue growth and strategic expansions, Metropolis Healthcare is setting new benchmarks in the diagnostics segment, promising a healthier future for millions.
